Distribution of anti-factor Xa activity in patients with nonvalvular atrial fibrillation receiving 15 mg dose of edoxaban

被引：0

作者：

Hiramatsu, Shotaro ^{[1
]}

Osanai, Hiroyuki ^{[2
]}

Sakai, Yuichiro ^{[2
]}

Sogo, Yoshiki ^{[2
]}

Tanaka, Yuki ^{[3
]}

Matsumoto, Hikari ^{[4
]}

Miyamoto, Shun ^{[5
]}

Tagahara, Kensuke ^{[4
]}

Arai, Kenji ^{[2
]}

Watanabe, Takashi ^{[2
]}

Sakamoto, Yusuke ^{[2
]}

Sakaguchi, Teruhiro ^{[2
]}

Oguchi, Shioh ^{[2
]}

Kanbara, Takahiro ^{[2
]}

Nakashima, Yoshihito ^{[2
]}

Asano, Hiroshi ^{[2
]}

Ajioka, Masayoshi ^{[2
]}

机构：

[1] Gifu Prefectural Tajimi Hosp, Dept Cardiol, 5 161 Maehata Cho, Tajimi, Gifu 5078522, Japan

[2] Tosei Gen Hosp, Dept Cardiol, Seto, Aichi, Japan

[3] Kumiai Kosei Hosp, Dept Cardiol, Takayama, Gifu, Japan

[4] Nagoya Univ Hosp, Dept Cardiol, Nagoya, Aichi, Japan

[5] Japanese Red Cross Aichi Med Ctr Nagoya Daiichi Ho, Dept Cardiol, Nagoya, Aichi, Japan

来源：

JOURNAL OF ARRHYTHMIA | 2024年

关键词：

anticoagulant; anti-factor Xa; atrial fibrillation; edoxaban; stroke; LABORATORY MEASUREMENT; ANTICOAGULANT ACTIVITY; JAPANESE PATIENTS; APIXABAN; WARFARIN;

D O I：

10.1002/joa3.13139

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Background: The distribution of anti-factor Xa activity (AXA) in patients with nonvalvular atrial fibrillation (NVAF) taking edoxaban 15 mg has not been fully elucidated. Methods and Results: The trough and peak AXA were measured in 19 NVAF patients taking edoxaban 15 mg. We compared these results with those in patients taking edoxaban 30 mg. The peak AXA differed significantly between the 15 mg and the 30 mg groups (0.74 +/- 0.40 IU/mL vs. 1.25 +/- 0.48 IU/mL, respectively; p < 0.0001). Conclusions: Peak but trough AXA in the patients receiving edoxaban 15 mg were significantly lower than those in patients receiving edoxaban 30 mg.

引用

页数：5

共 50 条

[1] Distribution of Anti-Factor Xa Activity in Patients on Edoxaban Therapy for Non-Valvular Atrial Fibrillation
Osanai, Hiroyuki
Ajioka, Masayoshi
Masutomi, Tomohiro
Kuwayama, Tasuku
Ishihama, Sota
Takahashi, Maki
Kanbara, Takahiro
Inoue, Yosuke
Nakashima, Yoshihito
Asano, Hiroshi
Sakai, Kazuyoshi
[J]. CIRCULATION JOURNAL, 2016, 80 (03) : 745 - 747
[2] IMPACT OF RENAL FUNCTION ON ANTI-FACTOR XA ACTIVITY VALUES WITH EDOXABAN USE IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION
Ono, Ryohei
Fukushima, Kenichi
Takahashi, Hidehisa
Hori, Yasuhiko
Kobayashi, Yoshio
[J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2022, 79 (09) : 1788 - 1788
[3] Impact of Renal Function on Anti-factor Xa Activity Concentrations with Edoxaban Use in Patients with Non-valvular Atrial Fibrillation
Ono, Ryohei
Nishimura, Kazutaka
Takahashi, Hidehisa
Hori, Yasuhiko
Fukushima, Kenichi
Kobayashi, Yoshio
[J]. DRUGS IN R&D, 2022, 22 (04) : 281 - 288
[4] Impact of Renal Function on Anti-factor Xa Activity Concentrations with Edoxaban Use in Patients with Non-valvular Atrial Fibrillation
Ryohei Ono
Kazutaka Nishimura
Hidehisa Takahashi
Yasuhiko Hori
Kenichi Fukushima
Yoshio Kobayashi
[J]. Drugs in R&D, 2022, 22 : 281 - 288
[5] Measurement of Anti-Factor Xa Activity in Patients on Apixaban for Non-Valvular Atrial Fibrillation
Osanai, Hiroyuki
Ajioka, Masayoshi
Masutomi, Tomohiro
Kuwayama, Tasuku
Ishihama, Sota
Sakamato, Yusuke
Otaka, Naoya
Sakaguchi, Teruhiro
Inoue, Yosuke
Kanbara, Takahiro
Nakashima, Yoshihito
Asano, Hiroshi
Sakai, Kazuyoshi
[J]. CIRCULATION JOURNAL, 2015, 79 (12) : 2584 - 2590
[6] COMPARISON OF ANTI-FACTOR XA ACTIVITY VALUES ON EDOXABAN THERAPY IN RELATION TO BASELINE RENAL FUNCTION IN PATIENTS WITHATRIAL FIBRILLATION
Ono, Ryohei
Fukushima, Kenichi
Takahashi, Hidehisa
Hori, Yasuhiko
Kobayashi, Yoshio
[J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2021, 77 (18) : 1800 - 1800
[7] Edoxaban in Japanese Patients With Nonvalvular Atrial Fibrillation - Not the Same Dose for Everybody
Roldan, Vanessa
Marin, Francisco
Lip, Gregory Y. H.
[J]. CIRCULATION JOURNAL, 2012, 76 (08) : 1826 - 1827
[8] The distribution of anti-factor Xa activity value, PT and APTT at peak and trough times in patients with direct anti-factor Xa inhibitors
Ono, R.
Fukushima, K.
Yamazaki, T.
Takahashi, H.
Hori, Y.
[J]. EUROPEAN HEART JOURNAL, 2020, 41 : 3368 - 3368
[9] Comparison of Anti-factor Xa Activity Among Three Different Factor Xa Inhibitors in Non-valvular Atrial Fibrillation Patients with Renal Impairment
Akihiro Tobe
Hiroyuki Osanai
Akihito Tanaka
Teruhiro Sakaguchi
Takahiro Kambara
Yoshihito Nakashima
Hiroshi Asano
Hideki Ishii
Masayoshi Ajioka
Toyoaki Murohara
[J]. Clinical Drug Investigation, 2020, 40 : 567 - 573
[10] Comparison of Anti-factor Xa Activity Among Three Different Factor Xa Inhibitors in Non-valvular Atrial Fibrillation Patients with Renal Impairment
Tobe, Akihiro
Osanai, Hiroyuki
Tanaka, Akihito
Sakaguchi, Teruhiro
Kambara, Takahiro
Nakashima, Yoshihito
Asano, Hiroshi
Ishii, Hideki
Ajioka, Masayoshi
Murohara, Toyoaki
[J]. CLINICAL DRUG INVESTIGATION, 2020, 40 (06) : 567 - 573

← 1 2 3 4 5 →